WO2014141844A1 - 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム - Google Patents
血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム Download PDFInfo
- Publication number
- WO2014141844A1 WO2014141844A1 PCT/JP2014/053997 JP2014053997W WO2014141844A1 WO 2014141844 A1 WO2014141844 A1 WO 2014141844A1 JP 2014053997 W JP2014053997 W JP 2014053997W WO 2014141844 A1 WO2014141844 A1 WO 2014141844A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- frequency
- blood sample
- electrical characteristics
- electrical
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 398
- 239000008280 blood Substances 0.000 title claims abstract description 398
- 238000000034 method Methods 0.000 title description 40
- 238000011156 evaluation Methods 0.000 claims abstract description 129
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 109
- 238000005259 measurement Methods 0.000 claims abstract description 105
- 230000008859 change Effects 0.000 claims abstract description 54
- 238000005534 hematocrit Methods 0.000 claims abstract description 49
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 35
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 35
- 238000011158 quantitative evaluation Methods 0.000 claims abstract description 30
- 238000004458 analytical method Methods 0.000 claims description 99
- 238000004062 sedimentation Methods 0.000 claims description 69
- 230000023555 blood coagulation Effects 0.000 claims description 43
- 230000015572 biosynthetic process Effects 0.000 claims description 23
- 230000036962 time dependent Effects 0.000 claims description 19
- 230000011132 hemopoiesis Effects 0.000 claims description 7
- 230000002123 temporal effect Effects 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 abstract description 56
- 206010039238 Rouleaux formation Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 238000012854 evaluation process Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/22—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
- G01N27/221—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance by investigating the dielectric properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
- G01N2015/055—Investigating sedimentation of particle suspensions in blood for hematocrite determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
Definitions
- This technology relates to a blood condition analyzer. More specifically, a blood state analysis device, a blood state analysis system, a blood state analysis method, and a blood state analysis apparatus capable of analyzing a hematocrit value and / or hemoglobin amount, red blood cell formation of red blood cells, etc. from the electrical characteristics of the blood sample, and
- the present invention relates to a program for causing a computer to realize the method.
- Non-patent Document 1 As a method for obtaining the volume fraction of cells in the cell suspension, the low-frequency electrical conductivity of the suspension (frequency of 100 kHz or less) and the low-frequency electrical conductivity of the solvent not containing cells (frequency of 100 kHz or less) There is a known technique using non-patent document 1 (Non-patent Document 1). For example, in a suspension in which spherical cells are thinly dispersed, the volume fraction of cells can be obtained as in the following mathematical formula (1).
- erythrocyte replenishment is formed such that the aggregate grows linearly in the initial stage and then takes a spherical structure (Non-Patent Document 2). Aggregates that have grown to a spherical structure begin to settle (red blood cell sedimentation (blood sedimentation or red sedimentation)).
- red blood cell sedimentation blood sedimentation or red sedimentation
- blood sedimentation is promoted by infections and the like, and has been used as an important item of blood tests since ancient times.
- Patent Literature 1 discloses a technique for acquiring information related to blood coagulation from the dielectric constant of blood. “A pair of electrodes and an alternating voltage are applied to the pair of electrodes at predetermined time intervals. Application means, measurement means for measuring the dielectric constant of blood disposed between the pair of electrodes, and dielectric constant of blood measured at the time interval after the action of the anticoagulant acting on the blood is released And a blood coagulation system analyzer having an analysis means for analyzing the degree of the function of the blood coagulation system.
- the initial process of erythropoiesis can be evaluated quantitatively, it is expected to correlate with blood sedimentation, and it is possible to predict the rate of erythrocyte sedimentation without waiting for the blood sedimentation to progress. Can be realized.
- the main object of the present technology is to provide a technology capable of analyzing the hematocrit value and / or the amount of hemoglobin, the formation of red blood cells, and the like of the blood sample based on the electrical characteristics of the blood sample.
- a blood state analyzing apparatus having an erythrocyte quantitative evaluation unit that evaluates a hematocrit value and / or a hemoglobin amount based on an electrical characteristic of a blood sample at a frequency of 2 to 25 MHz is provided.
- a blood reimbursement evaluation unit that evaluates the formation of red blood cells by dividing the time-dependent data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz.
- the electrical characteristics change over time includes the electrical characteristics of the blood sample at the time when the recurring progressed, and the electrical characteristics of the blood sample before the recurring progress. Can be used.
- the time-dependent change data of the electrical characteristics may be time-change data of the electrical characteristics of the blood sample at a frequency of 100 kHz to 40 MHz.
- the blood state analysis apparatus may include a blood sedimentation evaluation unit that evaluates the degree of erythrocyte sedimentation based on the cash formation evaluation evaluated by the blood currency evaluation unit.
- the blood state analysis apparatus may include a blood coagulation evaluation unit that evaluates the degree of blood coagulation based on the electrical characteristics of the blood sample.
- the blood condition analysis apparatus may include a measurement unit that measures the electrical characteristics of the blood sample over time.
- an electrical characteristic measurement device including a measurement unit that measures electrical characteristics of blood over time, A blood state analysis apparatus comprising an erythrocyte quantitative evaluation unit for evaluating a hematocrit value and / or a hemoglobin amount based on electrical characteristics of a blood sample at a frequency of 2 to 25 MHz; There is provided a blood state analysis system.
- an electrical property measuring device including a measurement unit that measures electrical properties of blood over time, Blood comprising a blood reimbursement evaluation unit that evaluates the formation of red blood cells by dividing the time-dependent data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz.
- a state analyzer There is provided a blood state analysis system.
- the blood state analysis system may include a server including an information storage unit that stores a measurement result of the electrical characteristic measurement device and / or an analysis result of the blood state analysis device.
- the server may be connected to the electrical characteristic measuring device and / or the blood state analyzing device via a network.
- the present technology further provides a blood state analysis method for performing an erythrocyte quantitative evaluation step of evaluating a hematocrit value and / or a hemoglobin amount based on an electrical characteristic of a blood sample at a frequency of 2 to 25 MHz.
- a blood change evaluation step for evaluating red blood cell formation by dividing the time-dependent data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz.
- a blood state analysis method to be performed is provided.
- this technology provides a blood condition analysis program that enables a computer to realize a red blood cell quantitative evaluation function that evaluates the hematocrit value and / or the amount of hemoglobin based on the electrical characteristics of a blood sample at a frequency of 2 to 25 MHz. To do. Moreover, a blood change evaluation function for evaluating the formation of red blood cells by dividing the time-dependent data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz. Providing a blood condition analysis program to be realized on a computer.
- the present technology it is possible to analyze the hematocrit value and / or hemoglobin amount of the blood sample, the formation of red blood cells, and the like based on the electrical characteristics of the blood sample, thereby predicting the erythrocyte sedimentation rate. It is possible to realize a speedy inspection.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing substitute graph showing the relationship between the dielectric constant and hematocrit value at each frequency obtained in Example 1.
- FIG. 6 is a drawing-substituting graph showing a correlation coefficient between a dielectric constant and a hematocrit value at each frequency obtained in Example 1.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. 10 is a drawing-substituting graph showing the relationship between the blood change evaluation value ( ⁇ ) and the erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- FIG. FIG. 6 is a drawing-substituting graph showing a correlation coefficient between a blood change evaluation value ( ⁇ ) and an erythrocyte sedimentation rate (ESR) at each frequency obtained in Example 2.
- Blood condition analyzer 1 (1) Red blood cell quantitative evaluation unit 11 (2) Blood reimbursement evaluation unit 12 (3) Blood sedimentation evaluation unit 13 (4) Blood coagulation evaluation unit 14 (5) Measuring unit 15 (6) Storage unit 16 (7) Blood sample Blood state analysis system 10 (1) Electrical characteristic measuring apparatus 101 (2) Blood condition analyzer 1 (3) Server 102 (4) Display unit 103 (5) User interface 104 3. Blood state analysis method (1) Red blood cell quantitative evaluation process I (2) Blood reimbursement evaluation process II (3) Blood sedimentation evaluation process III (4) Blood coagulation evaluation process IV (5) Measurement process V 4). Blood condition analysis program
- FIG. 1 is a schematic conceptual diagram schematically showing the concept of a blood state analysis apparatus 1 according to the present technology.
- the blood state analysis apparatus 1 according to the present technology includes at least the red blood cell quantity evaluation unit 11 or the blood reimbursement evaluation unit 12. Moreover, the blood sedimentation evaluation part 13, the blood coagulation evaluation part 14, the measurement part 15, the memory
- Red blood cell quantitative evaluation unit 11 1 is a schematic conceptual diagram schematically showing the concept of the first embodiment of the blood state analyzing apparatus 1 according to the present technology.
- the erythrocyte quantity evaluation unit 11 evaluates the hematocrit value and / or hemoglobin amount based on the electrical characteristics of the blood sample at a specific frequency.
- the present inventors have found that the electrical characteristics of blood samples at a frequency of 2 to 25 MHz are not easily affected by red blood cell coinage, and that fluctuations are small until the blood clotting reaction reaches a certain level. .
- the electrical characteristics of a blood sample at a frequency of 2 to 25 MHz are found to correlate with the hematocrit value and the amount of hemoglobin obtained by a general conventional blood test (see Example 1), and blood at a frequency of 2 to 25 MHz is found.
- a technique for evaluating the hematocrit value and / or the amount of hemoglobin from the electrical characteristics of the sample was established.
- the electrical characteristics of the blood sample are measured by the measurement unit 15 when the measurement unit 15 described later is provided in the external electrical property measurement device or the blood state analysis device 1 according to the present technology. These data can be used as they are. Alternatively, data obtained by removing noise from raw data can be used.
- Examples of the electrical characteristics of blood that can be used in the blood state analysis apparatus 1 according to the present technology include dielectric constant, impedance, admittance, capacitance, conductance, conductivity, phase angle, and the like. These electrical characteristics can be converted into each other by the mathematical formulas shown in Table 1 below. Therefore, for example, the evaluation result obtained by evaluating the hematocrit value and / or the amount of hemoglobin using the dielectric constant measurement result of the blood sample is the same as the evaluation result obtained when the impedance measurement result of the same blood sample is used. Many of these electrical quantities and physical property values can be described using complex numbers, thereby simplifying the conversion formula.
- the specific frequency of the electrical characteristics of blood that can be used in the blood state analysis apparatus 1 according to the present technology is not particularly limited as long as it is in the range of 2 to 25 MHz, but is preferably 2 to 10 MHz.
- an electrical characteristic of 2 MHz or higher the influence of blood change can be minimized.
- accurate evaluation can be performed by using electrical characteristics of 10 MHz or less.
- the electrical characteristics at the earliest possible stage after the measurement is started as the electrical characteristics of the blood used in the blood state analysis apparatus 1 according to the first embodiment. Specifically, it is preferable to use electrical characteristics within 3 minutes after the release of anticoagulation by the anticoagulant. This is because, within 3 minutes after the release of anticoagulation, the effects of blood recognition and coagulation can be minimized.
- Blood reimbursement evaluation unit 12 1 is a schematic conceptual diagram schematically showing the concept of the second embodiment of the blood state analyzing apparatus 1 according to the present technology.
- the blood change evaluation unit 12 evaluates the formation of red blood cells by dividing the temporal change data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz. .
- the specific frequency of the temporal change data of the electrical characteristics of the blood sample that can be used in the blood condition analyzer 1 according to the second embodiment is not particularly limited as long as the effect of the present technology is not impaired.
- the value obtained by correcting the time-dependent data of the electrical characteristics in this frequency range with the electrical measurement data correlating with the hematocrit value and / or hemoglobin amount is correlated with the erythrocyte sedimentation rate (ESR) measured by a general conventional method. It is because the nature is high.
- ESR erythrocyte sedimentation rate
- the electrical measurement data correlated with the hematocrit value and / or hemoglobin amount used for correction is the same as the electrical characteristics used in the first embodiment. I'll omit the explanation here.
- FIG. 1 is a schematic conceptual diagram schematically showing the concept of the third embodiment of the blood state analyzing apparatus 1 according to the present technology.
- a red blood cell quantity evaluation unit 11 and a blood reimbursement evaluation unit 12 are provided in the same apparatus.
- the hematocrit value is provided based on the electrical measurement data correlated with the hematocrit value and / or the hemoglobin amount by providing both the red blood cell quantity evaluation unit 11 and the blood reimbursement evaluation unit 12. It is possible to simultaneously evaluate the formation of red blood cells by correcting the time-dependent data using the electrical measurement data while evaluating the hemoglobin amount.
- Blood sedimentation evaluation unit 13 1 is a schematic conceptual diagram schematically showing the concept of the fourth embodiment of the blood state analyzing apparatus 1 according to the present technology.
- the blood reimbursement evaluation unit 12 and the blood sedimentation evaluation unit 13 are provided in the same apparatus.
- the blood sedimentation evaluation unit 13 evaluates the degree of erythrocyte sedimentation based on the cash formation evaluation evaluated by the blood cash evaluation unit 12.
- the blood sedimentation evaluation unit 13 is not essential in the blood state analysis device 1 according to the present technology. For example, based on the cash formation evaluation evaluated by the blood reimbursement evaluation unit 12, for example, an electronic computer outside the device is used. It is also possible to evaluate the degree of erythrocyte sedimentation.
- the present inventors have found that the monetary evaluation value calculated by the blood monetary evaluation unit 12 is highly correlated with the erythrocyte sedimentation rate (ESR). Therefore, by providing the blood sedimentation evaluation unit 13 in the blood state analysis apparatus 1 according to the present technology, the erythrocyte sedimentation rate (ESR) can be obtained at an early stage before blood sedimentation occurs.
- ESR erythrocyte sedimentation rate
- Blood coagulation evaluation unit 14 1 is a schematic conceptual diagram schematically showing the concept of the fifth embodiment of the blood state analyzing apparatus 1 according to the present technology.
- an erythrocyte quantitative evaluation unit 11, a blood change evaluation unit 12, a blood sedimentation evaluation unit 13, a blood coagulation evaluation unit 14, and a measurement unit 15 are provided in the same apparatus.
- the blood coagulation evaluation unit 14 evaluates the degree of blood coagulation based on the electrical characteristics of the blood sample.
- the blood coagulation evaluation unit 14 is not essential in the blood state analysis apparatus 1 according to the present technology. For example, based on the electrical characteristics of the blood sample used in the red blood cell quantity evaluation unit 11, for example, an electronic computer or the like outside the apparatus. It is also possible to evaluate the degree of blood coagulation using
- one or more known techniques for obtaining information on blood coagulation from the electrical characteristics such as dielectric constant can be freely selected. Can be used.
- the blood coagulation evaluation unit 14 in the blood state analysis apparatus 1 according to the present technology, in addition to the evaluation of the hematocrit value and the amount of hemoglobin, the evaluation of the monetary formation and the blood sedimentation from the measured electrical characteristics, The degree can be analyzed simultaneously in one device. As a result, a plurality of important blood test results can be obtained by a single measurement, and it is possible to realize cost reduction and test time reduction.
- the measurement unit 15 measures the electrical characteristics of blood at an arbitrary frequency over time.
- the measurement unit 15 is not essential, and data measured using an external electrical characteristic measurement apparatus can also be used.
- the measuring unit 15 can include one or a plurality of blood sample holding units.
- the blood sample holding unit is not essential.
- the measuring unit 15 can be designed in a form in which a known cartridge type measurement container or the like can be installed.
- the form of the blood sample holding unit is not particularly limited as long as the blood sample to be measured can be held in the measurement unit 15, and can be designed in a free form. it can.
- one or a plurality of cells provided on the substrate can function as a blood sample holding unit, or one or a plurality of containers can function as a blood sample holding unit.
- the form is not particularly limited.
- the blood sample to be measured can be held, a cylindrical body, a polygon having a polygon (triangle, square or more) in cross section. Design freely according to the state of blood sample and the measurement method, such as cylinders, cones, polygonal cones with a polygonal cross section (triangle, square or more), or a combination of one or more of these. can do.
- the material constituting the container is not particularly limited, and can be freely selected within a range that does not affect the state of the blood sample to be measured and the measurement purpose.
- the type of resin that can be used is not particularly limited, and one or more resins that can be used for holding a blood sample can be freely selected and used.
- hydrophobic and insulating polymers and copolymers such as polypropylene, polymethyl methacrylate, polystyrene, acrylic, polysulfone, polytetrafluoroethylene, and blend polymers may be used.
- the blood sample holding part is formed of one or more resins selected from polypropylene, polystyrene, acrylic, and polysulfone. This is because these resins have a property of low coagulation activity against blood.
- the blood sample holder is configured to be able to be sealed while holding the blood sample. However, if the time required for measuring the electrical characteristics of the blood sample can be stagnated and the measurement is not affected, the airtight configuration is not necessary.
- the specific introduction and sealing method of the blood sample to the blood sample holding part is not particularly limited, and can be introduced by a free method according to the form of the blood sample holding part.
- a blood sample holder is provided with a lid, and after introducing the blood sample using a pipette or the like, the lid is closed and sealed, or an injection needle is inserted from the outer surface of the blood sample holder, and the blood sample After injecting, a method of sealing the penetrating portion of the injection needle with grease or the like is included.
- the measurement unit 15 can include one or more application units.
- this application unit is not essential.
- an external application device can be used by designing the blood sample holding unit so that an electrode can be inserted from the outside.
- the application unit applies a predetermined voltage to the blood sample at each set measurement interval, starting from the time when a command to start measurement is received or the time when the power of the blood state analyzer 1 is turned on. Apply.
- the number of electrodes used as a part of the application unit and the material constituting the electrodes are not particularly limited as long as the effects of the present technology are not impaired, and any number of electrodes can be configured using a free material.
- any number of electrodes can be configured using a free material.
- titanium, aluminum, stainless steel, platinum, gold, copper, graphite and the like can be mentioned.
- the measuring unit 15 can also perform a plurality of measurements.
- a method of performing a plurality of measurements for example, a method of performing a plurality of measurements simultaneously by providing a plurality of measurement units 15, a method of performing a plurality of measurements by scanning one measurement unit 15, and moving a blood sample holding unit
- a method of performing a plurality of measurements by performing the above, a method of selecting one or a plurality of measurement units 15 provided with a plurality of measurement units 15 and actually performing measurement by switching, and the like can be mentioned.
- Storage unit 16 The blood condition analysis apparatus 1 according to the present technology stores the evaluation results in the red blood cell quantitative evaluation unit 11, the blood reimbursement evaluation unit 12, the blood sedimentation evaluation unit 13, and the blood coagulation evaluation unit 14, and the measurement results in the measurement unit 15. Storage unit 16 can be provided. In the blood state analysis apparatus 1 according to the present technology, the storage unit 16 is not essential, and each result can be stored by connecting an external storage device.
- the storage unit 16 may be provided separately for each evaluation unit and measurement unit, or each result in each evaluation unit and measurement unit may be provided in one storage unit 16. It is also possible to design so that
- the blood sample that can be measured is not particularly limited as long as it is a sample containing blood, and can be freely selected.
- Specific examples of the blood sample may include whole blood, plasma, or a sample containing blood components such as diluted solutions and / or drug additives.
- FIG. 2 is a schematic conceptual diagram schematically showing the concept of the blood state analysis system 10 according to the present technology.
- the blood state analysis system 10 according to the present technique is roughly provided with at least an electrical characteristic measurement device 101 and a blood state analysis device 1.
- the server 102, the display unit 103, the user interface 104, and the like can be provided as necessary.
- each part will be described in detail.
- the electrical characteristic measuring apparatus 101 includes a measurement unit 15 that measures the electrical characteristics of blood at an arbitrary frequency over time.
- the details of the measurement unit 15 are the same as those of the measurement unit 15 in the blood state analysis apparatus 1 described above.
- the blood state analysis apparatus 1 includes at least a red blood cell quantitative evaluation unit 11 or a blood reimbursement evaluation unit 12. Moreover, the blood sedimentation evaluation part 13, the blood coagulation evaluation part 14, etc. can also be provided as needed. In addition, each part with which the blood state analyzer 1 is provided is the same as the detail of the blood state analyzer 1 mentioned above.
- the server 102 includes a storage unit 16 that stores measurement results obtained by the electrical characteristic measurement device 101 and / or analysis results obtained by the blood state analysis device 1.
- the details of the storage unit 16 are the same as those of the storage unit 16 in the blood state analyzer 1 described above.
- Display unit 103 The display unit 103 displays each evaluation result in the erythrocyte quantitative evaluation unit 11, blood change evaluation unit 12, blood sedimentation evaluation unit 13, blood coagulation evaluation unit 14, measurement result in the measurement unit 15, and the like. Although a plurality of display units 103 can be provided for each data and result to be displayed, all data and results can be displayed on one display unit 103.
- the user interface 104 is a part for a user to operate. The user can access each part of the blood state analysis system 10 according to the present technology through the user interface 104.
- the electrical characteristic measurement device 101, the blood state analysis device 1, the server 102, the display unit 103, and the user interface 104 may be connected to each other via a network.
- FIG. 3 is a flowchart of a blood state analysis method according to the present technology.
- the red blood cell quantitative evaluation step I and / or the blood replenishment evaluation step II are performed. Further, if necessary, blood sedimentation evaluation process III, blood coagulation evaluation process IV, measurement process V, and the like can be performed. Hereinafter, each step will be described in detail.
- the erythrocyte quantitative evaluation step I is a step of evaluating the hematocrit value and / or the amount of hemoglobin based on the electrical characteristics of the blood sample at a frequency of 2 to 25 MHz.
- the details of the evaluation method performed in the red blood cell quantitative evaluation step I are the same as the evaluation method executed by the red blood cell quantitative evaluation unit 11 of the blood state analyzer 1 described above.
- the blood reimbursement evaluation step II evaluates the formation of recurrent red blood cells by dividing the temporal change data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz. It is a process.
- the details of the evaluation method performed in the blood change evaluation step II are the same as the evaluation method executed by the blood change evaluation unit 12 of the blood state analysis apparatus 1 described above.
- the blood sedimentation evaluation step III is a step of evaluating the degree of erythrocyte sedimentation based on the recurring formation evaluation evaluated in the blood remuneration evaluation step II.
- the details of the evaluation method performed in the blood sedimentation evaluation step III are the same as the evaluation method executed by the blood sedimentation evaluation unit 13 of the blood state analysis apparatus 1 described above.
- the blood coagulation evaluation step IV is a step of evaluating the degree of blood coagulation based on the electrical characteristics of the blood sample.
- the details of the evaluation method performed in the blood coagulation evaluation step IV are the same as the evaluation method executed by the blood coagulation evaluation unit 14 of the blood state analysis apparatus 1 described above.
- Measurement process V is a process of measuring the electrical characteristics of blood at an arbitrary frequency over time.
- the measurement process V is not an essential process, and it is also possible to perform analysis using data measured in advance.
- the details of the measurement method performed in the measurement step V are the same as the measurement method executed by the measurement unit 15 of the blood state analysis device 1 described above.
- the blood state analysis program according to the present technology is a program for causing a computer to realize a red blood cell quantitative evaluation function and / or a blood change evaluation function. Further, if necessary, it is possible to cause a computer to realize a blood sedimentation evaluation function, a blood coagulation evaluation function, and the like.
- the blood state analysis program according to the present technology is a program for causing a computer to realize the blood state analysis method according to the present technology described above. Therefore, the details of each function are the same as the respective steps of the blood state analysis method described above, and thus the description thereof is omitted here.
- Example 1 the correlation between the electrical characteristics of the blood sample and the hematocrit value was examined.
- the dielectric constant was used as an example of the electrical characteristics of the blood sample.
- the correlation coefficient suddenly decreased at 32 MHz or higher.
- the correlation coefficient at 10 MHz to 25 MHz is not so high, but this is because the electrical response due to red blood cells becomes weak at higher frequencies, and is more susceptible to noise. Use a more accurate measuring instrument.
- This correlation coefficient is expected to increase.
- the correlation coefficient is generally high at low frequencies, and the maximum value is at 5 MHz.
- the closer to 1 MHz the more easily affected by red blood cell replenishment as described above. This effect is particularly great when the time from mixing the aqueous calcium solution to starting the measurement is not accurate.
- the dielectric constant changes with time even immediately after the start of measurement, so that it is considered that stable analysis becomes more difficult. Considering these matters, it was concluded that the hematocrit value can be evaluated with high accuracy by using the electrical characteristics of the blood sample at a frequency of 2 to 25 MHz.
- the amount of hemoglobin is also a quantitative measurement value of red blood cells. Therefore, the electrical characteristics of a blood sample at a frequency of 2 to 25 MHz are considered to correlate with the amount of hemoglobin. That is, it is suggested that the amount of hemoglobin can be evaluated with high accuracy by using the electrical characteristics of a blood sample at a frequency of 2 to 25 MHz.
- Example 2 the correlation between the blood change evaluation value calculated by the blood change evaluation unit 12 of the blood condition analysis apparatus 1 according to the present technology and the erythrocyte sedimentation rate (ESR) was examined.
- the dielectric constant was used as an example of the electrical characteristics of the blood sample.
- ESR erythrocyte sedimentation rate
- the present technology it is possible to simultaneously analyze the evaluation of the hematocrit value and the amount of hemoglobin, the formation of remuneration, blood sedimentation, and blood coagulation from the electrical characteristics of the measured blood sample. As a result, a plurality of important blood test results can be obtained by a single measurement, and it is possible to realize cost reduction and test time reduction.
- each measurement value can be used for correction of each analysis, which can contribute to the construction of advanced diagnostic techniques.
- a blood state analysis apparatus comprising an erythrocyte quantitative evaluation unit for evaluating a hematocrit value and / or a hemoglobin amount based on an electrical characteristic of a blood sample at a frequency of 2 to 25 MHz.
- Blood comprising a blood reimbursement evaluation unit that evaluates the formation of red blood cells by dividing the time-dependent data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz.
- State analysis device comprising an erythrocyte quantitative evaluation unit for evaluating a hematocrit value and / or a hemoglobin amount based on an electrical characteristic of a blood sample at a frequency of 2 to 25 MHz.
- the blood state analyzing apparatus according to any one of (2) to (5), further comprising an erythrocyte quantitative evaluation unit that evaluates a hematocrit value and / or a hemoglobin amount based on an electrical characteristic of a blood sample at a frequency of 2 to 25 MHz.
- the blood state analysis apparatus according to any one of (1) to (6), further including a blood coagulation evaluation unit that evaluates the degree of blood coagulation based on the electrical characteristics of the blood sample.
- the blood state analysis apparatus according to any one of (1) to (7), further comprising a measurement unit that measures electrical characteristics of the blood sample over time.
- An electrical property measuring device comprising a measuring unit for measuring electrical properties of blood over time;
- a blood state analysis apparatus comprising an erythrocyte quantitative evaluation unit for evaluating a hematocrit value and / or a hemoglobin amount based on electrical characteristics of a blood sample at a frequency of 2 to 25 MHz;
- a blood state analysis system comprising an electrical property measuring device comprising a measuring unit for measuring electrical properties of blood over time;
- Blood comprising a blood reimbursement evaluation unit that evaluates the formation of red blood cells by dividing the time-dependent data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz.
- a state analyzer A blood state analysis system.
- a server including an information storage unit that stores a measurement result in the electrical characteristic measurement device and / or an analysis result in the blood state analysis device.
- the server is connected to the electrical characteristic measurement device and / or the blood state analysis device via a network.
- Blood that performs a blood change evaluation step for evaluating red blood cell formation by dividing the time-dependent change data of the electrical characteristics of the blood sample at a predetermined frequency by the electrical measurement data of the blood sample at a frequency of 2 to 25 MHz.
- State analysis method 15
- a blood condition analysis program for causing a computer to realize a red blood cell quantitative evaluation function for evaluating a hematocrit value and / or a hemoglobin amount based on an electrical characteristic of a blood sample at a frequency of 2 to 25 MHz.
- 1 blood state analysis device
- 11 red blood cell quantitative evaluation unit
- 12 blood reimbursement evaluation unit
- 13 blood sedimentation evaluation unit
- 14 blood coagulation evaluation unit
- 15 measurement unit
- 16 storage unit
- 10 blood state Analysis system
- 101 electrical characteristic measuring device
- 102 server
- 103 display unit
- 104 user interface
- I red blood cell quantitative evaluation process
- II blood replenishment evaluation process
- III blood sedimentation evaluation process
- IV blood Coagulation evaluation process
- V Measurement process
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Ecology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
即ち、本技術では、まず、周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を有する血液状態解析装置を提供する。
また、所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価部を有する血液状態解析装置を提供する。
本技術に係る血液状態解析装置において、前記電気的特性の経時変化データとしては、連銭が進行した時間における血液試料の電気的特性と、連銭が進行する前の血液試料の電気的特性との差分を用いることができる。
また、本技術に係る血液状態解析装置において、前記電気的特性の経時変化データは、周波数100kHz~40MHzにおける血液試料の電気的特性の経時変化データを用いることができる。
本技術に係る血液状態解析装置には、前記血液連銭評価部によって評価された連銭形成評価に基づいて、赤血球沈降の程度を評価する血沈評価部を備えることも可能である。
また、本技術に係る血液状態解析装置には、血液試料の電気的特性に基づいて、血液凝固の程度を評価する血液凝固評価部を備えることも可能である。
更に、本技術に係る血液状態解析装置には、血液試料の電気的特性を経時的に測定する測定部を備えることも可能である。
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える血液状態解析装置と、
を有する血液状態解析システムを提供する。
また、血液の電気的特性を経時的に測定する測定部を備える電気的特性測定装置と、
所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価部を備える血液状態解析装置と、
を有する血液状態解析システムを提供する。
本技術に係る血液状態解析システムには、前記電気的特性測定装置での測定結果及び/又は前記血液状態解析装置での解析結果を記憶する情報記憶部を備えるサーバーを備えることも可能である。
この場合、前記サーバーは、ネットワークを介して、前記電気的特性測定装置及び/又は前記血液状態解析装置と接続することもできる。
また、所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価工程を行う血液状態解析方法を提供する。
また、所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価機能をコンピューターに実現させるための血液状態解析プログラムを提供する。
1.血液状態解析装置1
(1)赤血球量的評価部11
(2)血液連銭評価部12
(3)血沈評価部13
(4)血液凝固評価部14
(5)測定部15
(6)記憶部16
(7)血液試料
2.血液状態解析システム10
(1)電気的特性測定装置101
(2)血液状態解析装置1
(3)サーバー102
(4)表示部103
(5)ユーザーインターフェース104
3.血液状態解析方法
(1)赤血球量的評価工程I
(2)血液連銭評価工程II
(3)血沈評価工程III
(4)血液凝固評価工程IV
(5)測定工程V
4.血液状態解析プログラム
図1は、本技術に係る血液状態解析装置1の概念を模式的に示す模式概念図である。本技術に係る血液状態解析装置1は、赤血球量的評価部11又は血液連銭評価部12を少なくとも備える。また、必要に応じて、血沈評価部13、血液凝固評価部14、測定部15、記憶部16などを備えることもできる。以下、各部について詳細に説明する。
図1中符号Aは、本技術に係る血液状態解析装置1の第1実施形態の概念を模式的に示す模式概念図である。赤血球量的評価部11では、特定の周波数における血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する。本発明者らは、周波数2~25MHzにおける血液試料の電気的特性が、赤血球連銭による影響を受けにくいこと、また、血液凝固反応が一定レベルに達するまでの間は変動が小さいことを見出した。そして、周波数2~25MHzにおける血液試料の電気的特性は、一般的な従来の血液検査で得られるヘマトクリット値及びヘモグロビン量と、相関することを見出し(実施例1参照)、周波数2~25MHzにおける血液試料の電気的特性から、ヘマトクリット値及び/又はヘモグロビン量を評価する技術を確立させた。
図1中符号Bは、本技術に係る血液状態解析装置1の第2実施形態の概念を模式的に示す模式概念図である。血液連銭評価部12では、所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する。
図1中符号Dは、本技術に係る血液状態解析装置1の第4実施形態の概念を模式的に示す模式概念図である。第4実施形態は、血液連銭評価部12と血沈評価部13とが、同一装置内に備えられた形態である。血沈評価部13では、前記血液連銭評価部12によって評価された連銭形成評価に基づいて、赤血球沈降の程度を評価する。この血沈評価部13は、本技術に係る血液状態解析装置1では必須ではなく、例えば、前記血液連銭評価部12で評価された連銭形成評価に基づいて、装置外の例えば電子計算機などを用いて赤血球沈降の程度を評価することも可能である。
図1中符号Eは、本技術に係る血液状態解析装置1の第5実施形態の概念を模式的に示す模式概念図である。第5実施形態は、赤血球量的評価部11、血液連銭評価部12、血沈評価部13、血液凝固評価部14、測定部15が、同一装置内に備えられた形態である。血液凝固評価部14では、血液試料の電気的特性に基づいて、血液凝固の程度を評価する。この血液凝固評価部14は、本技術に係る血液状態解析装置1では必須ではなく、例えば、前記赤血球量的評価部11で用いる血液試料の電気的特性に基づいて、装置外の例えば電子計算機などを用いて血液凝固の程度を評価することも可能である。
測定部15では、任意の周波数における血液の電気的特性を経時的に測定する。本技術に係る血液状態解析装置1において、この測定部15は必須ではなく、外部の電気的特性測定装置を用いて測定したデータを用いることも可能である。
本技術に係る血液状態解析装置1には、赤血球量的評価部11、血液連銭評価部12、血沈評価部13及び血液凝固評価部14における各評価結果や、測定部15における測定結果を記憶する記憶部16を備えることができる。本技術に係る血液状態解析装置1において、記憶部16は必須ではなく、外部の記憶装置を接続して、各結果を記憶することも可能である。
本技術に係る血液状態解析装置1において、測定対象とすることが可能な血液試料は、血液を含有する試料であれば特に限定されず、自由に選択することができる。血液試料の具体例としては、全血、血漿、またはこれらの希釈液および/または薬剤添加物などの血液成分を含有する試料などを挙げることができる。
図2は、本技術に係る血液状態解析システム10の概念を模式的に示す模式概念図である。本技術に係る血液状態解析システム10は、大別して、電気的特性測定装置101と、血液状態解析装置1と、を少なくとも備える。また、必要に応じて、サーバー102、表示部103、ユーザーインターフェース104などを備えることもできる。以下、各部について詳細に説明する。
電気的特性測定装置101は、任意の周波数における血液の電気的特性を経時的に測定する測定部15を備える。測定部15の詳細は、前述した血液状態解析装置1における測定部15と同一である。
血液状態解析装置1は、赤血球量的評価部11又は血液連銭評価部12を少なくとも備える。また、必要に応じて、血沈評価部13、血液凝固評価部14などを備えることもできる。なお、血液状態解析装置1に備える各部は、前述した血液状態解析装置1の詳細と同一である。
サーバー102には、電気的特性測定装置101での測定結果及び/又は血液状態解析装置1での解析結果を記憶する記憶部16を備える。記憶部16の詳細は、前述した血液状態解析装置1における記憶部16と同一である。
表示部103では、赤血球量的評価部11、血液連銭評価部12、血沈評価部13及び血液凝固評価部14における各評価結果や、測定部15における測定結果などが表示される。表示部103は、表示するデータや結果毎に、複数設けることも可能であるが、一つの表示部103に、全てのデータや結果を表示することも可能である。
ユーザーインターフェース104は、ユーザーが操作するための部位である。ユーザーは、ユーザーインターフェース104を通じて、本技術に係る血液状態解析システム10の各部にアクセスすることができる。
図3は、本技術に係る血液状態解析方法のフローチャートである。本技術に係る血液状態解析方法では、赤血球量的評価工程I及び/又は血液連銭評価工程IIを行う。また、必要に応じて、血沈評価工程III、血液凝固評価工程IV、測定工程Vなどを行うこともできる。以下、各工程について詳細に説明する。
赤血球量的評価工程Iは、周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する工程である。赤血球量的評価工程Iで行う評価方法の詳細は、前述した血液状態解析装置1の赤血球量的評価部11で実行される評価方法と同一である。
血液連銭評価工程IIは、所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する工程である。血液連銭評価工程IIで行う評価方法の詳細は、前述した血液状態解析装置1の血液連銭評価部12で実行される評価方法と同一である。
血沈評価工程IIIは、前記血液連銭評価工程IIにおいて評価された連銭形成評価に基づいて、赤血球沈降の程度を評価する工程である。血沈評価工程IIIで行う評価方法の詳細は、前述した血液状態解析装置1の血沈評価部13で実行される評価方法と同一である。
血液凝固評価工程IVは、血液試料の電気的特性に基づいて、血液凝固の程度を評価する工程である。血液凝固評価工程IVで行う評価方法の詳細は、前述した血液状態解析装置1の血液凝固評価部14で実行される評価方法と同一である。
測定工程Vは、任意の周波数における血液の電気的特性を経時的に測定する工程である。本技術に係る血液状態解析方法において、この測定工程Vは必須の工程ではなく、予め測定されたデータを用いて解析を行うことも可能である。測定工程Vで行う測定方法の詳細は、前述した血液状態解析装置1の測定部15で実行される測定方法と同一である。
本技術に係る血液状態解析プログラムは、赤血球量的評価機能及び/又は血液連銭評価機能をコンピューターに実現させるためのプログラムである。また、必要に応じて、血沈評価機能、血液凝固評価機能などをコンピューターに実現させることも可能である。
(1)電気的特性の測定
抗凝固剤として、クエン酸ナトリウムが内包された真空採血管を用いて採血した血液試料を、予め37℃で保温し、測定開始直前に0.25M塩化カルシウム水溶液を血液1mL当たり85μLの濃度で加えて血液凝固反応を開始させた。この血液試料について、血液凝固反応開始1分後に、温度37℃、周波数域1MHz~40MHzにおいて、誘電率測定を行った。
前記電気的特性の測定で用いた血液試料について、一般的な従来の方法を用いてヘマトクリット値を測定した。
各周波数における誘電率とヘマトクリット値との関係を、図4~11の図面代用グラフに示す。また、各周波数における誘電率とヘマトクリット値とのそれぞれの相関係数を、下記表2及び図12に示す。
(1)電気的特性の測定
抗凝固剤として、クエン酸ナトリウムが内包された真空採血管を用いて採血した血液試料を、予め37℃で保温し、測定開始直前に0.25M塩化カルシウム水溶液を血液1mL当たり85μLの濃度で加えて血液凝固反応を開始させた。この血液試料について、血液凝固反応開始1分後から測定間隔1分毎に、温度37℃、周波数域50kHz~40MHzにおいて、誘電率測定を行った。
連銭が進行した時間における血液試料の電気的特性(誘電率)と、連銭が進行する前の血液試料の電気的特性(誘電率)との差分を、周波数6.3MHzにおける血液試料の電気的測定データで割ることにより、血液連銭評価値(γ)を算出した。連銭が進行した時間における血液試料の電気的特性(誘電率)としては10分後の誘電率を、連銭が進行する前の血液試料の電気的特性(誘電率)としては、2分後と3分後の誘電率の平均を用いた。
前記電気的特性の測定で用いた血液試料について、一般的な従来の方法を用いて赤血球沈降速度(ESR)を測定した。
各周波数における血液連銭評価値(γ)と赤血球沈降速度(ESR)との関係を、図13~27の図面代用グラフに示す。また、各周波数における血液連銭評価値(γ)と赤血球沈降速度(ESR)とのそれぞれの相関係数を、下記表3及び図28に示す。
(1)
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える血液状態解析装置。
(2)
所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価部を備える血液状態解析装置。
(3)
前記電気的特性の経時変化データは、連銭が進行した時間における血液試料の電気的特性と、連銭が進行する前の血液試料の電気的特性との差分である(2)に記載の血液状態解析装置。
(4)
前記電気的特性の経時変化データは、周波数100kHz~40MHzにおける血液試料の電気的特性の経時変化データである(2)又は(3)に記載の血液状態解析装置。
(5)
前記血液連銭評価部によって評価された連銭形成評価に基づいて、赤血球沈降の程度を評価する血沈評価部を備える(2)から(4)のいずれかに記載の血液状態解析装置。
(6)
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える(2)から(5)のいずれかに記載の血液状態解析装置。
(7)
血液試料の電気的特性に基づいて、血液凝固の程度を評価する血液凝固評価部を備える(1)から(6)のいずれかに記載の血液状態解析装置。
(8)
血液試料の電気的特性を経時的に測定する測定部を備える(1)から(7)のいずれかに記載の血液状態解析装置。
(9)
血液の電気的特性を経時的に測定する測定部を備える電気的特性測定装置と、
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える血液状態解析装置と、
を有する血液状態解析システム。
(10)
血液の電気的特性を経時的に測定する測定部を備える電気的特性測定装置と、
所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価部を備える血液状態解析装置と、
を有する血液状態解析システム。
(11)
前記電気的特性測定装置での測定結果及び/又は前記血液状態解析装置での解析結果を記憶する情報記憶部を備えるサーバーを備える(9)又は(10)に記載の血液状態解析システム。
(12)
前記サーバーは、ネットワークを介して、前記電気的特性測定装置及び/又は前記血液状態解析装置と接続されている(11)に記載の血液状態解析システム。
(13)
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価工程を行う血液状態解析方法。
(14)
所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価工程を行う血液状態解析方法。
(15)
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価機能をコンピューターに実現させるための血液状態解析プログラム。
(16)
所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価機能をコンピューターに実現させるための血液状態解析プログラム。
Claims (16)
- 周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える血液状態解析装置。
- 所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価部を備える血液状態解析装置。
- 前記電気的特性の経時変化データは、連銭が進行した時間における血液試料の電気的特性と、連銭が進行する前の血液試料の電気的特性との差分である請求項2記載の血液状態解析装置。
- 前記電気的特性の経時変化データは、周波数100kHz~40MHzにおける血液試料の電気的特性の経時変化データである請求項2記載の血液状態解析装置。
- 前記血液連銭評価部によって評価された連銭形成評価に基づいて、赤血球沈降の程度を評価する血沈評価部を備える請求項2記載の血液状態解析装置。
- 周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える請求項2記載の血液状態解析装置。
- 血液試料の電気的特性に基づいて、血液凝固の程度を評価する血液凝固評価部を備える請求項1又は2に記載の血液状態解析装置。
- 血液試料の電気的特性を経時的に測定する測定部を備える請求項1又は2に記載の血液状態解析装置。
- 血液の電気的特性を経時的に測定する測定部を備える電気的特性測定装置と、
周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価部を備える血液状態解析装置と、
を有する血液状態解析システム。 - 血液の電気的特性を経時的に測定する測定部を備える電気的特性測定装置と、
所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価部を備える血液状態解析装置と、
を有する血液状態解析システム。 - 前記電気的特性測定装置での測定結果及び/又は前記血液状態解析装置での解析結果を記憶する情報記憶部を備えるサーバーを備える請求項9又は10記載の血液状態解析システム。
- 前記サーバーは、ネットワークを介して、前記電気的特性測定装置及び/又は前記血液状態解析装置と接続されている請求項11記載の血液状態解析システム。
- 周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価工程を行う血液状態解析方法。
- 所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価工程を行う血液状態解析方法。
- 周波数2~25MHzにおける血液試料の電気的特性に基づいて、ヘマトクリット値及び/又はヘモグロビン量を評価する赤血球量的評価機能をコンピューターに実現させるための血液状態解析プログラム。
- 所定の周波数における血液試料の電気的特性の経時変化データを、周波数2~25MHzにおける血液試料の電気的測定データで除することにより、赤血球の連銭形成を評価する血液連銭評価機能をコンピューターに実現させるための血液状態解析プログラム。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480012889.3A CN105008907B (zh) | 2013-03-15 | 2014-02-20 | 血液状态分析装置、血液状态分析系统、血液状态分析方法 |
US14/772,550 US10648936B2 (en) | 2013-03-15 | 2014-02-20 | Blood condition analyzing device, blood condition analyzing system, blood conditon analyzing method, and blood condition analyzing program for causing computer to execute the method |
JP2015505350A JP6421749B2 (ja) | 2013-03-15 | 2014-02-20 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
EP14763083.4A EP2975388A4 (en) | 2013-03-15 | 2014-02-20 | Blood condition analyzing device, blood condition analyzing system, blood condition analyzing method, and blood condition analyzing program for realizing method on computer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013052664 | 2013-03-15 | ||
JP2013-052664 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014141844A1 true WO2014141844A1 (ja) | 2014-09-18 |
Family
ID=51536520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/053997 WO2014141844A1 (ja) | 2013-03-15 | 2014-02-20 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
Country Status (5)
Country | Link |
---|---|
US (1) | US10648936B2 (ja) |
EP (1) | EP2975388A4 (ja) |
JP (3) | JP6421749B2 (ja) |
CN (1) | CN105008907B (ja) |
WO (1) | WO2014141844A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016042944A1 (ja) * | 2014-09-19 | 2016-03-24 | ソニー株式会社 | 電気的特性測定装置及びプログラム |
WO2016158139A1 (ja) * | 2015-03-31 | 2016-10-06 | ソニー株式会社 | 電気的特性測定装置、電気的特性測定方法、血液状態解析システム、及び該方法をコンピューターに実現させるための電気的特性測定用プログラム |
JPWO2017130528A1 (ja) * | 2016-01-29 | 2018-11-15 | ソニー株式会社 | 血液凝固系解析装置、血液凝固系解析システム、血液凝固系解析方法及び血液凝固系解析装置用パラメーターの決定方法 |
JP2019049561A (ja) * | 2013-03-15 | 2019-03-28 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108931632A (zh) | 2013-01-28 | 2018-12-04 | 索尼公司 | 电测量容器、阻抗测量装置及其操作方法 |
CN105008906B (zh) | 2013-03-13 | 2020-01-07 | 索尼公司 | 血液状态分析装置、血液状态分析系统 |
EP2980570B1 (en) | 2013-03-29 | 2020-07-22 | Sony Corporation | Blood state evaluation system, blood state evaluation method, and program |
EP2980571A4 (en) | 2013-03-29 | 2016-10-26 | Sony Corp | BLOOD STATUS ANALYSIS DEVICE, BLOOD STATUS ANALYSIS SYSTEM, BLOOD CONDITION ANALYSIS METHOD, AND PROGRAM |
JP6442858B2 (ja) | 2014-04-17 | 2018-12-26 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
JP6579100B2 (ja) | 2014-04-17 | 2019-09-25 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、及び該方法をコンピューターに実現させるための血液状態解析プログラム |
CA2974621C (en) * | 2017-07-27 | 2019-11-05 | Macdon Industries Ltd. | Agricultural header with ground engaging gauge member for above ground cutting |
CN110501504B (zh) * | 2018-05-16 | 2024-03-12 | 深圳市理邦精密仪器股份有限公司 | 血液含量检测方法和系统 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0399254A (ja) * | 1989-09-13 | 1991-04-24 | Toyota Central Res & Dev Lab Inc | ヘマトクリット測定装置 |
JP2000503772A (ja) * | 1996-01-19 | 2000-03-28 | コールター インターナショナル コーポレイション | 個々の赤血球のヘモグロビン含有量の測定のための方法及び装置 |
JP2010181400A (ja) | 2009-01-08 | 2010-08-19 | Sony Corp | 血液凝固系解析装置、血液凝固系解析方法及びプログラム |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352557A (en) * | 1979-10-20 | 1982-10-05 | Ernst Leitz Wetzlar Gmbh | Determining a test value corresponding to blood subsidence |
US6128518A (en) * | 1990-10-04 | 2000-10-03 | Microcor, Inc. | System and method for in-vivo hematocrit measurement using impedance and pressure plethysmography |
US7291310B2 (en) | 2002-12-17 | 2007-11-06 | The Regents Of The University Of Michigan | Microsystem for determining clotting time of blood and low-cost, single-use device for use therein |
JP4893526B2 (ja) | 2007-08-10 | 2012-03-07 | ソニー株式会社 | 細胞の物性値測定方法及び物性測定装置 |
JP5098817B2 (ja) | 2008-05-29 | 2012-12-12 | ソニー株式会社 | 物性測定装置及び物性測定方法 |
JP5556144B2 (ja) | 2009-11-26 | 2014-07-23 | ソニー株式会社 | 血球細胞分析装置、血球細胞分析方法及び血球細胞分析システム |
EP2395353B1 (en) * | 2010-06-09 | 2018-08-22 | Apex Biotechnology Corp. | Device and method for measuring prothrombin time and hematocrit by analyzing change in reactance in a sample |
JP5768422B2 (ja) * | 2011-03-17 | 2015-08-26 | ソニー株式会社 | 血液凝固系解析方法および血液凝固系解析装置 |
KR101333225B1 (ko) * | 2011-10-27 | 2013-11-26 | 광주과학기술원 | 헤마토크리트 측정 방법 및 장치 |
RU2015128049A (ru) | 2013-01-18 | 2017-01-16 | Сони Корпорейшн | Устройство для измерения электрических характеристик |
CN108931632A (zh) | 2013-01-28 | 2018-12-04 | 索尼公司 | 电测量容器、阻抗测量装置及其操作方法 |
JP6299609B2 (ja) | 2013-02-08 | 2018-03-28 | ソニー株式会社 | 微小粒子分析装置及び微小粒子分析システム |
CN105008906B (zh) | 2013-03-13 | 2020-01-07 | 索尼公司 | 血液状态分析装置、血液状态分析系统 |
WO2014141844A1 (ja) | 2013-03-15 | 2014-09-18 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
WO2014155932A1 (ja) | 2013-03-26 | 2014-10-02 | ソニー株式会社 | 測定装置及び測定方法 |
EP2980571A4 (en) | 2013-03-29 | 2016-10-26 | Sony Corp | BLOOD STATUS ANALYSIS DEVICE, BLOOD STATUS ANALYSIS SYSTEM, BLOOD CONDITION ANALYSIS METHOD, AND PROGRAM |
EP2980570B1 (en) | 2013-03-29 | 2020-07-22 | Sony Corporation | Blood state evaluation system, blood state evaluation method, and program |
JP6442858B2 (ja) | 2014-04-17 | 2018-12-26 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
JP6579100B2 (ja) | 2014-04-17 | 2019-09-25 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、及び該方法をコンピューターに実現させるための血液状態解析プログラム |
-
2014
- 2014-02-20 WO PCT/JP2014/053997 patent/WO2014141844A1/ja active Application Filing
- 2014-02-20 US US14/772,550 patent/US10648936B2/en active Active
- 2014-02-20 EP EP14763083.4A patent/EP2975388A4/en not_active Withdrawn
- 2014-02-20 JP JP2015505350A patent/JP6421749B2/ja active Active
- 2014-02-20 CN CN201480012889.3A patent/CN105008907B/zh active Active
-
2018
- 2018-10-16 JP JP2018194805A patent/JP6638789B2/ja active Active
-
2019
- 2019-12-25 JP JP2019234408A patent/JP7103336B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0399254A (ja) * | 1989-09-13 | 1991-04-24 | Toyota Central Res & Dev Lab Inc | ヘマトクリット測定装置 |
JP2000503772A (ja) * | 1996-01-19 | 2000-03-28 | コールター インターナショナル コーポレイション | 個々の赤血球のヘモグロビン含有量の測定のための方法及び装置 |
JP2010181400A (ja) | 2009-01-08 | 2010-08-19 | Sony Corp | 血液凝固系解析装置、血液凝固系解析方法及びプログラム |
Non-Patent Citations (5)
Title |
---|
A.IRIMAJIRI ET AL.: "Dielectric monitoring of rouleaux formation in human whole blood: a feasibility study", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1290, no. 3, 1 January 1996 (1996-01-01), pages 207 - 209, XP055281069, DOI: 10.1016/0304-4165(96)00048-7 * |
AKIHIKO IRIMAJIRI ET AL.: "Zenketsu no Yuden Kyodo kara Mita Sekkekkyu Gyoshu (Renzen Keisei", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 78, no. 5, 1 January 2000 (2000-01-01), pages 162 - 165, XP008151323 * |
BLOOD, vol. 70, 1987, pages 1572 - 1576 |
PHYS. MED. BIOL., vol. 54, 2009, pages 2395 - 2405 |
See also references of EP2975388A4 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019049561A (ja) * | 2013-03-15 | 2019-03-28 | ソニー株式会社 | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム |
US10648936B2 (en) | 2013-03-15 | 2020-05-12 | Sony Corporation | Blood condition analyzing device, blood condition analyzing system, blood conditon analyzing method, and blood condition analyzing program for causing computer to execute the method |
WO2016042944A1 (ja) * | 2014-09-19 | 2016-03-24 | ソニー株式会社 | 電気的特性測定装置及びプログラム |
EP3196638A4 (en) * | 2014-09-19 | 2018-03-21 | Sony Corporation | Electrical characteristic measuring device and program |
US10578604B2 (en) | 2014-09-19 | 2020-03-03 | Sony Corporation | Electrical characteristic measuring device |
WO2016158139A1 (ja) * | 2015-03-31 | 2016-10-06 | ソニー株式会社 | 電気的特性測定装置、電気的特性測定方法、血液状態解析システム、及び該方法をコンピューターに実現させるための電気的特性測定用プログラム |
CN107407650A (zh) * | 2015-03-31 | 2017-11-28 | 索尼公司 | 电特性测量装置、电特性测量方法、血液状况分析系统以及用于计算机化该方法的电特性测量程序 |
JPWO2016158139A1 (ja) * | 2015-03-31 | 2018-01-25 | ソニー株式会社 | 電気的特性測定装置、電気的特性測定方法、血液状態解析システム、及び該方法をコンピューターに実現させるための電気的特性測定用プログラム |
US10634660B2 (en) | 2015-03-31 | 2020-04-28 | Sony Corporation | Electrical characteristic measurement device, electrical characteristic measurement method, and blood condition analysis system |
JPWO2017130528A1 (ja) * | 2016-01-29 | 2018-11-15 | ソニー株式会社 | 血液凝固系解析装置、血液凝固系解析システム、血液凝固系解析方法及び血液凝固系解析装置用パラメーターの決定方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105008907B (zh) | 2018-12-28 |
JP2019049561A (ja) | 2019-03-28 |
CN105008907A (zh) | 2015-10-28 |
JP7103336B2 (ja) | 2022-07-20 |
JPWO2014141844A1 (ja) | 2017-02-16 |
JP2020056798A (ja) | 2020-04-09 |
EP2975388A1 (en) | 2016-01-20 |
JP6638789B2 (ja) | 2020-01-29 |
US10648936B2 (en) | 2020-05-12 |
US20160018346A1 (en) | 2016-01-21 |
EP2975388A4 (en) | 2017-02-22 |
JP6421749B2 (ja) | 2018-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6421749B2 (ja) | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム | |
JP5549484B2 (ja) | 液体試料の電気特性測定のためのサンプルカートリッジと装置 | |
JP6690680B2 (ja) | 血液状態解析装置、血液状態解析システム、および血液状態解析プログラム | |
JP6442858B2 (ja) | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム | |
CN107003296B (zh) | 溶血检测方法和系统 | |
EP2947451A1 (en) | Electrical characteristic measurement device | |
EP3133395B1 (en) | Blood condition analysis device, blood condition analysis system, blood condition analysis method, and blood condition analysis program for enabling computer to perform said method | |
Lapić et al. | Analytical validation of the iSED automated analyzer for erythrocyte sedimentation rate | |
JP6747491B2 (ja) | 血液状態解析装置、血液状態解析システム、血液状態解析方法、および該方法をコンピューターに実現させるための血液状態解析プログラム | |
CN107407650B (zh) | 电特性测量装置、电特性测量方法、血液状况分析系统以及用于计算机化该方法的电特性测量程序 | |
JP2016510119A (ja) | 電気化学的な分析物測定において回復パルスからの情報を使用する方法およびデバイス、装置とそれらを組み込むシステム | |
JP6876920B2 (ja) | 電気的特性測定装置、電気的特性測定システム、電気的特性測定方法、及び該方法をコンピューターに実現させるための電気的特性測定用プログラム | |
Parri et al. | Measurement System for Blood Sedimentation Rate Through Impedenzimetric Sampling | |
EP3196638A1 (en) | Electrical characteristic measuring device and program | |
US20210263052A1 (en) | Blood coagulation system analysis device | |
WO2016013300A1 (ja) | 電気的測定用カートリッジ、生体試料用電気的測定装置、生体試料用電気的測定システム及び生体試料用電気的測定方法 | |
WO2016158148A1 (ja) | 電気的測定方法、電気的測定装置、及び血液状態解析システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14763083 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015505350 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014763083 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14772550 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |